Constipation Treatment Market Overview: Major Segments, Strategic Developments, and Leading Companies

The constipation treatment market is gaining considerable attention as health challenges related to bowel function become more prevalent worldwide. With increasing awareness about gut health and advances in medical care, this sector is poised for significant growth. Let's explore the market's projected expansion, the key players involved, emerging trends, and important segmentation details shaping its future.

Long-Term Outlook for the Constipation Treatment Market Size Through 2030
The constipation treatment market is forecasted to experience substantial growth in the coming years. By 2030, its size is expected to reach $18.72 billion, growing at a compound annual growth rate (CAGR) of 8.0%. This upward trend is largely driven by the rising prevalence of chronic constipation, increased opioid consumption, heightened awareness of gut health, the expansion of specialized gastroenterology services, and improved access to innovative treatment options. Key trends during this period include a growing preference for prescription medications targeting chronic constipation, greater adoption of probiotics and digestive health supplements, a shift toward drugs with targeted mechanisms, increased focus on managing opioid-induced constipation, and a rise in online pharmacy distribution channels.

Download a free sample of the constipation treatment market report:
https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies in the Constipation Treatment Industry
Several prominent pharmaceutical and biotech companies dominate the constipation treatment landscape. These include Pfizer, Johnson & Johnson, AbbVie, Bayer, Sanofi, Fresenius Kabi, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Bausch Health Companies Inc, Salix Pharmaceuticals Inc, Prestige Consumer Healthcare Inc, Ironwood Pharmaceuticals Inc, Cosmo Pharmaceuticals NV, Ferring Pharmaceuticals, Probi AB, 4D Pharma plc, Abbott Laboratories, Albireo Pharma Inc, Ardelyx Inc, Synergy Pharmaceuticals Inc, Astellas Pharma Inc, and Allergan plc.

In March 2023, the French pharmaceutical company Ipsen acquired Albireo Pharma Inc., a US-based biotech firm focused on chronic constipation treatments, for an undisclosed sum. This acquisition strengthens Ipsen's portfolio in rare diseases and expands its footprint in constipation therapy development.

View the full constipation treatment market report:
https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends That Will Influence the Constipation Treatment Market
Innovation is a key focus for leading companies, with a growing emphasis on drug-free mechanical stimulation devices designed to address constipation effectively while minimizing side effects. These solutions cater to the needs of an aging population, increased opioid use, and preferences for non-pharmacological treatments.

One such innovation is the vibrating capsule, an ingestible, single-use device housing a mini vibration motor and battery encased in a medical-grade shell that stimulates the colon mechanically to encourage peristalsis. This technology offers predictable bowel movements without the systemic impacts commonly associated with laxatives or prescription prokinetics. For example, in May 2023, Vibrant Ltd., a US medical technology company, introduced Vibrant, an FDA-cleared vibrating capsule system for adults with chronic idiopathic constipation unresponsive to laxatives. The system features a reusable activation pod and a single-use capsule programmed to deliver about 190 vibration cycles per hour, stimulating colonic contractions in timed bursts.

Detailed Segmentation of the Global Constipation Treatment Market
The constipation treatment market is segmented comprehensively across therapeutic types, disease categories, and distribution channels:

1) Therapeutic Types:
- Laxatives
- Chloride Channel Activators
- Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs)
- Guanylate Cyclase-C (GC-C) Agonists
- Other Therapeutics

2) Disease Types:
- Chronic Idiopathic Constipation (CIC)
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Opioid-Induced Constipation (OIC)

3) Distribution Channels:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

Subcategories provide further detail within each therapeutic type:
- Laxatives include bulk-forming, osmotic, stimulant varieties, and stool softeners.
- Chloride channel activators cover lubiprostone-based and other formulations.
- PAMORAs are divided into methylnaltrexone, naloxegol, and other agents.
- GC-C agonists include linaclotide, plecanatide, and other related drugs.
- Other therapeutics encompass prokinetic agents, serotonin 5-HT4 receptor agonists, and herbal or alternative remedies.

This structured segmentation offers a clear picture of the market's complexity and the varied treatment options available to address different types of constipation.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.